Share this video  

ESMO 2018 | Changes in the staging system for HPV+ cancer patients

Hisham Mehanna • 29 Nov 2018
ESMO 2018
General

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, discussing recent changes to the old staging system for HPV-positive cancer patients. Changes to clinical staging and pathological staging are explained.

More from Hisham Mehanna

1:43
The challenge of validating new biomarkers
Hisham Mehanna • 29 Nov 2018
2:27
Improving patient selection for surgical candidates with head and neck cancer
Hisham Mehanna • 28 Sep 2019
3:58
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
Hisham Mehanna • 30 Sep 2019
1:23
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
Hisham Mehanna • 29 Nov 2018

Related Videos

2:49
Pharmacovigilance and the purpose of clinical trials
Diana Lüftner • 21 Sep 2017
2:00
The NCRI: supporting and expediting UK cancer research
Richard Stephens • 8 Nov 2018
1:05
Critical data points in the production of biosimilars
Richard Markus • 26 Sep 2017
2:31
IO-chemo and IO-radio options for cancer treatment
John Bell • 8 Nov 2018
The content of VJOncology is intended for healthcare professionals